Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Company News
Events
Directory
Search
Close search
Home
Company
MedImmune Inc
MedImmune Inc
Activities:
Manufacturing
Research & Development
Pharmaceutical
X
LinkedIn
Trending Articles
Catalent and AstraZeneca to expand support for COVID-19 vaccine AZD1222
Catalent will prepare the Harmans facility, close to Baltimore-Washington International (BWI) airport, to enable multiple production trains to run in parallel to produce the...
Chemistry, manufacturing and control (CMC) as key drivers for drug discovery success
Embracing collaborative strategies not only accelerates drug development programmes but also fosters science-based milestone decisions, mitigates risks and prepares for...
LUNA 3: Rilzabrutinib Phase III immune thrombocytopenia trial meets primary endpoint
Rilzabrutinib met both the primary endpoint of durable platelet response and various secondary endpoints in patients who were refractory to prior therapy
Memel Biotech and Therabest collaborate to develop exosome-based cell therapies
The partnership will aim to develop, manufacture and distribute novel exosome cell therapies in a range of therapeutic areas
Ipsen and Skyhawk Therapeutics partner to develop RNA-targeting drug candidates
The USD $1.8bn deal will support the development of novel RNA-modulating drugs using Skyhawk's proprietary technology
Upcoming event
Cleanroom Conference UK
22–23 May 2024 | Exhibition | Birmingham, UK
See all
Related Content
Media
Merck is set to lead pharmaceutical licensing deals in 2018
GlobalData, a specialist data and analytics company, expects that 2018 is likely to be Merck’s year in terms of research and development collaboration
Research & Development
MedImmune and Abpro enter into a collaborative agreement for a novel bispecific antibody
Agreement to result in new spin out company, AbMed, as subsidiary of Abpro
Research & Development
AstraZeneca launches integrated genomics approach to transform drug discovery and development
The initiative includes new collaborations with Human Longevity, the Wellcome Trust Sanger Institute and The Institute for Molecular Medicine
Research & Development
AstraZeneca and Moderna Therapeutics link up to develop immuno-oncology mRNA therapeutics
Extension to an mRNA agreement for cardiovascular, metabolic and renal diseases set up in 2013
Manufacturing
Wacker Biotech grants MedImmune licence to use Esetec technology to manufacture antibody fragment
To help improve productivity and simplify the purification process
Research & Development
AstraZeneca signs third cancer deal in seven days
MedImmune enters into cancer vaccine collaboration and license agreement with Inovio Pharmaceuticals
Research & Development
Medimmune partners with the University of Sheffield to innovate cell factory technology
Partnership will create tools that could increase the yield and predictability of engineered proteins such as bispecific antibodies to treat a range of diseases
Subscribe now